OmniAb (NASDAQ:OABI – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.
Valuation and Earnings
This table compares OmniAb and Ernexa Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OmniAb | $26.39 million | 9.76 | -$62.03 million | ($0.58) | -3.09 |
| Ernexa Therapeutics | $580,000.00 | 16.78 | -$44.54 million | ($3.01) | -0.41 |
Profitability
This table compares OmniAb and Ernexa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | -301.83% | -23.14% | -20.59% |
| Ernexa Therapeutics | N/A | -1,950.55% | -304.60% |
Insider and Institutional Ownership
72.1% of OmniAb shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 8.6% of OmniAb shares are owned by company insiders. Comparatively, 4.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
OmniAb has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 6.41, meaning that its stock price is 541% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for OmniAb and Ernexa Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
| Ernexa Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
OmniAb currently has a consensus target price of $6.67, indicating a potential upside of 272.44%. Given OmniAb’s stronger consensus rating and higher probable upside, equities analysts clearly believe OmniAb is more favorable than Ernexa Therapeutics.
Summary
OmniAb beats Ernexa Therapeutics on 9 of the 14 factors compared between the two stocks.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
